Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.42)
# 984
Out of 4,996 analysts
208
Total ratings
50.81%
Success rate
3.13%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Overweight | $215 → $245 | $220.61 | +11.06% | 16 | Sep 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $975 → $825 | $724.54 | +13.87% | 13 | Aug 13, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $385.74 | +25.73% | 4 | Aug 5, 2025 | |
| AMGN Amgen | Reiterates: Neutral | $305 | $272.98 | +11.73% | 17 | Jun 24, 2025 | |
| BMY Bristol-Myers Squibb Company | Reiterates: Neutral | $55 | $44.12 | +24.66% | 16 | Apr 23, 2025 | |
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $695 | $563.90 | +23.25% | 20 | Apr 22, 2025 | |
| PFE Pfizer | Initiates: Neutral | $24 | $23.76 | +1.01% | 15 | Apr 22, 2025 | |
| PCVX Vaxcyte | Initiates: Overweight | n/a | $33.98 | - | 1 | Apr 22, 2025 | |
| MRK Merck & Co. | Initiates: Neutral | $85 | $78.56 | +8.20% | 11 | Apr 22, 2025 | |
| GILD Gilead Sciences | Assumes: Overweight | $125 | $112.10 | +11.51% | 15 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $142.00 | +16.20% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $25.30 | -20.95% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $137.37 | +31.03% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $100 | $81.39 | +22.87% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $33.62 | +78.47% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $1.22 | +145.88% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.29 | +597.67% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $50.40 | +88.49% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $13.20 | +51.52% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $62 → $73 | $79.69 | -8.40% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $3.10 | +287.10% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $2.70 | -44.44% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $2.25 | $1.24 | +81.45% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $217.51 | +74.70% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $82.70 | -0.85% | 5 | Jan 16, 2019 |
AbbVie
Sep 15, 2025
Maintains: Overweight
Price Target: $215 → $245
Current: $220.61
Upside: +11.06%
Eli Lilly and Company
Aug 13, 2025
Maintains: Overweight
Price Target: $975 → $825
Current: $724.54
Upside: +13.87%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $385.74
Upside: +25.73%
Amgen
Jun 24, 2025
Reiterates: Neutral
Price Target: $305
Current: $272.98
Upside: +11.73%
Bristol-Myers Squibb Company
Apr 23, 2025
Reiterates: Neutral
Price Target: $55
Current: $44.12
Upside: +24.66%
Regeneron Pharmaceuticals
Apr 22, 2025
Assumes: Overweight
Price Target: $695
Current: $563.90
Upside: +23.25%
Pfizer
Apr 22, 2025
Initiates: Neutral
Price Target: $24
Current: $23.76
Upside: +1.01%
Vaxcyte
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $33.98
Upside: -
Merck & Co.
Apr 22, 2025
Initiates: Neutral
Price Target: $85
Current: $78.56
Upside: +8.20%
Gilead Sciences
Apr 22, 2025
Assumes: Overweight
Price Target: $125
Current: $112.10
Upside: +11.51%
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $142.00
Upside: +16.20%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $25.30
Upside: -20.95%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $137.37
Upside: +31.03%
Aug 29, 2024
Initiates: Overweight
Price Target: $100
Current: $81.39
Upside: +22.87%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $33.62
Upside: +78.47%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $1.22
Upside: +145.88%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.29
Upside: +597.67%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $50.40
Upside: +88.49%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $13.20
Upside: +51.52%
Feb 29, 2024
Maintains: Overweight
Price Target: $62 → $73
Current: $79.69
Upside: -8.40%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $3.10
Upside: +287.10%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $2.70
Upside: -44.44%
Aug 16, 2022
Maintains: Equal-Weight
Price Target: $2.5 → $2.25
Current: $1.24
Upside: +81.45%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $217.51
Upside: +74.70%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $82.70
Upside: -0.85%